Compound astragalus polysaccharides and echinacea purpurea herb nanoemulsion adjuvant and preparation method thereof

Abstract

The invention discloses a compound astragalus polysaccharides and echinacea purpurea herb nanoemulsion adjuvant, the partical size of which is between 1nm and 100nm, and is composed by echinacea purpurea herb, astragalus polysaccharides, surface active agent, cosurfactant, oil and distilled water. The product presents clear light yellow liquid, has the partical size smaller than 100nm, has lower viscosity and better stability, does not need special emulation when seedling, and has low requirements on equipment and easy controlled product quality. By taking albumin egg OVA as model antigen, tests show that the compound astragalus polysaccharides and echinacea purpurea herb nanoemulsion adjuvant of the invention has better immunoreaction than using aluminium adjuvant in a certain dosage, has higher antibody titer, reduces the dosage of oil or antigen in the adjuvant, stimulates the reaction of Th1 and Th2, increases the immunization of the liquid and the cell of the an organism, and plays a good role of immune protection of the organism.

Description

Technical field [0001] The invention relates to the field of vaccine adjuvants, in particular to a compound astragalus polysaccharide and echinacea extract water-in-oil nanoemulsion adjuvant that can form a composition with an antigen, which has the immune effect of enhancing the antigen and is used for the prevention and treatment of animal diseases. Background technique [0002] In recent years, with the occurrence of more and more animal diseases or zoonotic diseases, the demand and requirements for vaccine production have also become higher. However, in the application of vaccines, many shortcomings are often found, and various problems have appeared: ① Although the current commercial inactivated vaccines and attenuated vaccines can alleviate clinical symptoms, they cannot prevent the reinfection of the virus and the detoxification of sick pigs; ②The pathogenicity of viruses isolated from various regions is often different, and even the repeatability of the same virus is not ...

AI Technical Summary

Problems solved by technology

However, many shortcomings are often found in the actual application of vaccines, and various problems have arisen: ① Although the current commercialized inactivated vaccines and attenuated vaccines can alleviate clinical symptoms, they cannot prevent the reinfection of the virus and the detoxification of sick pigs; ②The pathogenicity of viruses isolated from various places is often different, and even the repeatability of the same virus is not very good, and time-sensitive, resulting in the production of inactivated vaccines and attenuated vaccines are often not effective; ③Inactivated vaccines Although it is safe, the protection produced is not strong, and repeated immunizations are often required; ④Compared with inactivated vaccines, the immune response induced by attenuated vaccines lasts longer and is more effective, but it has the problem of dispersing the virus itself. And there is a potential danger of returning to strength

Oil adjuvants are widely used in inactivated vaccines for animals at present, but such adjuvants are usually water-in-oil emulsions, which are unstable and viscous, requiring force when injecting, and mineral oil is not easy to absorb in the body. Dispersion and metabolism, prone to local side effects such as erythema and pustules, affecting animal appearance and meat quality

Images